As Novartis A G (NVS) Shares Declined, Ngam Advisors LP Decreased Its Stake by $4.28 Million

May 3, 2018 - By Matthew Medley

Novartis AG (NYSE:NVS) Corporate Logo

Based on the latest 2017Q4 regulatory filing with the SEC, Ngam Advisors Lp reduced its stake in Novartis A G (NVS) by 5.76%. 51,531 shares were sold by Ngam Advisors Lp as the company’s stock declined 4.22% with the market. The major pharmaceuticals company at the end of 2017Q4 was valued at $70.74M. It’s down from 894,032 at the end of the previous reported quarter. Now it had 842,501 shares held by the institutional investor . Novartis A G has $177.50 billion MC. NVS is reaching $76.08 during the last trading session, after increased 0.38%.Novartis AG has volume of 532,430 shares. Since May 3, 2017 NVS has risen 5.79% and is uptrending. NVS underperformed by 5.76% the S&P 500.

The Ngam Advisors Lp’s stake in Abb Ltd (NYSE:ABB) was increased by 135,480 shares to 777,515 shares valued at $20.85M in 2017Q4, according to the filing. It manages about $16.78B and $9.82 billion US Long portfolio. For a total of 137,630 shares it increased its holding in Cognex Corp (NASDAQ:CGNX) by 67,694 shares in the quarter, and has risen its stake in Duke Realty Corp (NYSE:DRE).

Novartis AG (NYSE:NVS) Ratings Coverage

In total 3 analysts cover Novartis (NYSE:NVS). “Buy” rating has 0, “Sell” are 1, while 2 are “Hold”. 0 are bullish. With $100 highest and $98.0 lowest price target Novartis has $99 average price target or 30.13% above the current ($76.08) price. 3 are the (NYSE:NVS)’s analyst reports since December 6, 2017 according to StockzIntelligence Inc. In Wednesday, December 6 report Bank of America downgraded the stock to “Sell” rating. In Friday, February 2 report Cowen & Co maintained it with “Hold” rating and $98.0 target. On Thursday, January 25 Leerink Swann maintained Novartis AG (NYSE:NVS) with “Market Perform” rating.

Novartis AG (NYSE:NVS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: